荷兰低发病率国家肝细胞癌发病率、诊断、治疗及生存趋势:2009-2016年数据
该研究基于荷兰癌症登记处2009-2016年3838例肝细胞癌患者数据,分析发病率、诊断、治疗和生存趋势。结果显示接受抗癌治疗的患者比例从49%升至57%,肿瘤活检比例从51%降至42%,1年、3年和5年生存率均显著改善。接受抗癌治疗与生存改善相关,而年龄增长和晚期肿瘤分期与生存下降相关,且不同地区在 resection、消融和TACE/radioembolisation应用上存在显著差异。
要点
- 2009-2016年荷兰HCC患者接受抗癌治疗比例从49%升至57%,生存显著改善。
- 肿瘤活检比例从51%降至42%, resection和消融使用增加。
- 不同地区在 resection、消融和TACE/radioembolisation应用上存在显著差异。
核心结论
- 2009至2016年间,荷兰肝细胞癌患者接受抗癌治疗的比例增加,生存率改善。
- 不同地区之间在治疗方式的选择上存在显著差异。
研究设计与样本
- 基于荷兰癌症登记处的回顾性队列研究,纳入2009-2016年诊断为HCC的3838例患者。
- 分析发病率、诊断、各种治疗方式(除外肝移植)及区域治疗偏好的趋势,生存分析采用Kaplan-Meier曲线和多变量Cox比例风险回归模型。
主要发现
- 接受肿瘤活检的患者比例从2009-2010年的51%下降至2015-2016年的42%。
- 接受抗癌治疗的患者比例从2009-2010年的49%增加至2015-2016年的57%,主要由于 resection和消融使用增加。
- 进行 resection或处方索拉非尼的医院数量略有减少,而每年消融少于1例的医院数量增加。
- 在病例组合校正后,不同地区间 resection、消融和TACE/radioembolisation的应用存在显著差异(p < 0.05)。
- 研究期间HCC患者的1年、3年和5年生存率显著改善;接受抗癌治疗与生存改善相关,年龄增长和晚期肿瘤分期与生存下降相关。
临床怎么用
- 在低发病率国家,HCC的治疗模式随时间变化,抗癌治疗使用增加与生存改善相关。
- 临床实践中需注意地区间治疗差异,并关注年龄和肿瘤分期对预后的影响。
局限性
- 肝移植数据因不准确而未纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluation of the trends in incidence, diagnostics, treatment and survival of patients with hepatocellular carcinoma (HCC) in the Netherlands. METHOD: Data regarding incidence, diagnostics, primary treatment and survival of patients with HCC in the period 2009-2016 were obtained from the Netherlands Cancer Registry. Trends in incidence, diagnostics, various treatment modalities (except liver transplantation, due to inaccurate data) and regional treatment preferences were analysed. Survival was evaluated using Kaplan-Meier curves and multivariable Cox proportional hazard regression modelling. RESULTS: In the period of 2009-2016, 3838 patients were diagnosed with HCC. A distinct decrease in the percentage of patients who underwent tumour biopsy was observed (from 51% in 2009-2010 to 42% in 2015-2016). Percentage of patients who underwent cancer treatment increased markedly (from 49% in 2009-2010 to 57% in 2015-2016), mainly because of an increasing use of resection and ablation. The number of hospitals where resections were performed or sorafenib treatment prescribed decreased slightly. The number of hospitals sporadically (<1 ablation per year) performing ablations increased. There were significant differences between regions in the application of resection, ablation and transarterial chemoembolisation /radioembolisation (p < 0.05 after 'case mix'-correction). One-, 3- and 5-year survival of patients with HCC significantly improved in the studied period. Receiving cancer treatment was associated with increased survival, whereas increasing age and an advanced tumour stage were both associated with decreased survival. CONCLUSION: From 2009 to 2016, patients with hepatocellular carcinoma more often received cancer treatment and their survival improved. There were significant differences in types of treatment between various regions.
引用
- Reinders MTM, van Meer S, Burgmans MC, et al. Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country: Data from the Netherlands in the period 2009-2016. Eur J Cancer. 2020. PMID: 32799035. doi:10.1016/j.ejca.2020.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。